143 related articles for article (PubMed ID: 38091023)
1. Risk of Subsequent Vitiligo in Transplant Recipients With Comorbid Graft-vs-Host Disease.
Bang CH; Park HE; Kim YH; Jung JH; Lee JH; Park YM; Han JH
JAMA Dermatol; 2024 Feb; 160(2):194-198. PubMed ID: 38091023
[TBL] [Abstract][Full Text] [Related]
2. Skin Cancer Risk in Hematopoietic Stem-Cell Transplant Recipients Compared With Background Population and Renal Transplant Recipients: A Population-Based Cohort Study.
Omland SH; Gniadecki R; Hædersdal M; Helweg-Larsen J; Omland LH
JAMA Dermatol; 2016 Feb; 152(2):177-83. PubMed ID: 26454261
[TBL] [Abstract][Full Text] [Related]
3. Subsequent vitiligo after hematopoietic stem cell transplantation: A nationwide population-based cohort study from Korea.
Bae JM; Choi KH; Jung HM; Kim SY; Kim M; Kim GM; Yu DS; Lee YB
J Am Acad Dermatol; 2017 Mar; 76(3):459-463. PubMed ID: 27836331
[TBL] [Abstract][Full Text] [Related]
4. Clostridioides difficile Infection and Risk of Acute Graft-versus-Host Disease among Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Jabr R; El Atrouni W; Shune L; Telfah M; Gao G; He J; Abhyankar S; McGuirk J; Clough L
Transplant Cell Ther; 2021 Feb; 27(2):176.e1-176.e8. PubMed ID: 33830032
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
[TBL] [Abstract][Full Text] [Related]
6. Emergency Department Utilization Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Longitudinal Analysis of 557 Patients.
Cserna J; Baumann CK; Lobmeyr E; Grafeneder J; Ettl F; Eibensteiner F; Rabitsch W; Mitterbauer M; Knaus HA; Wohlfarth P
Transplant Cell Ther; 2023 May; 29(5):321.e1-321.e9. PubMed ID: 36842484
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and Risk Factors for Invasive Fungal Diseases among Allogeneic Hematopoietic Stem Cell Transplant Recipients in Korea: Results of "RISK" Study.
Choi JK; Cho SY; Yoon SS; Moon JH; Kim SH; Lee JH; Kim JS; Cheong JW; Jang JH; Seo BJ; Kim YJ; Lee HJ; Lee J; Lee JW; Lee DG
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1773-1779. PubMed ID: 28668492
[TBL] [Abstract][Full Text] [Related]
8. Severity of acute gastrointestinal graft-vs-host disease is associated with incidence of bloodstream infection after adult allogeneic hematopoietic stem cell transplantation.
Modi A; Rybicki L; Majhail NS; Mossad SB
Transpl Infect Dis; 2020 Feb; 22(1):e13217. PubMed ID: 31769584
[TBL] [Abstract][Full Text] [Related]
9. Vitiligo following stem-cell transplant.
Totani A; Amin H; Bacchi S; Lewis I
Bone Marrow Transplant; 2020 Feb; 55(2):332-340. PubMed ID: 31358916
[TBL] [Abstract][Full Text] [Related]
10. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
11. Long-term risk of tuberculosis in haematopoietic stem cell transplant recipients: a 10-year nationwide study.
Fan WC; Liu CJ; Hong YC; Feng JY; Su WJ; Chien SH; Chen TJ; Chiang CH
Int J Tuberc Lung Dis; 2015 Jan; 19(1):58-64. PubMed ID: 25519791
[TBL] [Abstract][Full Text] [Related]
12. Risk factors and characterization of vitiligo and alopecia areata in patients with chronic graft-vs-host disease.
Zuo RC; Naik HB; Steinberg SM; Baird K; Mitchell SA; Kuzmina Z; Pavletic SZ; Cowen EW
JAMA Dermatol; 2015 Jan; 151(1):23-32. PubMed ID: 25207994
[TBL] [Abstract][Full Text] [Related]
13. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140
[TBL] [Abstract][Full Text] [Related]
14. Corticosteroids as graft-versus-host disease prophylaxis for allogeneic hematopoietic cell transplant recipients with calcineurin inhibitor intolerance.
Puckrin R; Kwan ACF; Blosser N; Leyshon C; Duggan P; Daly A; Zepeda V; Stewart D; Chaudhry A; Storek J; Jamani K
Cytotherapy; 2023 Oct; 25(10):1101-1106. PubMed ID: 37306643
[TBL] [Abstract][Full Text] [Related]
15. Choosing Between Older Matched Sibling Donor and Younger Matched Unrelated Donor in Allogeneic Hematopoietic Cell Transplantation: Comparison of Clinical Outcomes in Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Pereira MP; Remberger M; Chen C; Gerbitz A; Kim DDH; Kumar R; Lam W; Law AD; Lipton JH; Michelis FV; Novitzky-Basso I; Viswabandya A; Mattsson J; Pasic I
Transplant Cell Ther; 2023 Nov; 29(11):697.e1-697.e10. PubMed ID: 37579919
[TBL] [Abstract][Full Text] [Related]
16. Severe sepsis in hematopoietic stem cell transplant recipients*.
Kumar G; Ahmad S; Taneja A; Patel J; Guddati AK; Nanchal R;
Crit Care Med; 2015 Feb; 43(2):411-21. PubMed ID: 25599465
[TBL] [Abstract][Full Text] [Related]
17. Solid organ transplantation after allogeneic hematopoietic stem cell transplantation: a retrospective, multicenter study of the EBMT.
Koenecke C; Hertenstein B; Schetelig J; van Biezen A; Dammann E; Gratwohl A; Ganser A; Schleuning M; Bornhäuser M; Jacobsen N; Kröger N; Niederwieser D; de Witte T; Ruutu T
Am J Transplant; 2010 Aug; 10(8):1897-906. PubMed ID: 20659095
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.
Holtick U; Albrecht M; Chemnitz JM; Theurich S; Skoetz N; Scheid C; von Bergwelt-Baildon M
Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD010189. PubMed ID: 24748537
[TBL] [Abstract][Full Text] [Related]
19. Cancer incidence in immunocompromised patients: a single-center cohort study.
Ilham S; Willis C; Kim K; Chung KC; Wood BM; Tan MS; Tan CJ; Nguyen DT; Brixner DI; Stenehjem DD
BMC Cancer; 2023 Jan; 23(1):33. PubMed ID: 36624408
[TBL] [Abstract][Full Text] [Related]
20. Triple-Drug Graft-versus-Host Disease Prophylaxis after HLA-Matched Unrelated Donor Nonmyeloablative Allogenic Hematopoietic Stem Cell Transplantation.
Wegener A; Andersen NS; Friis LS; Petersen SL; Schjødt I; Kornblit B; Sengeløv H; Gjærde LK
Transplant Cell Ther; 2023 Sep; 29(9):575.e1-575.e6. PubMed ID: 37301257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
